Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net selling from northbound capital, with a total net sell of 204.41 billion HKD on August 28, 2023, indicating a cautious sentiment among investors [1]. Group 1: Northbound Capital Activity - Northbound capital saw a net sell of 132.97 billion HKD through the Shanghai Stock Connect and 71.44 billion HKD through the Shenzhen Stock Connect [1]. - The most bought stocks included SMIC (00981), Kangfang Biotech (09926), and Huahong Semiconductor (01347), while the most sold stocks were the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises Index (02828), and Tencent (00700) [1]. Group 2: Stock Performance and Predictions - SMIC received a net buy of 8.92 billion HKD, while Huahong Semiconductor had a net buy of 4.63 billion HKD, reflecting a renewed interest in chip stocks [6]. - Kangfang Biotech saw a net buy of 5.11 billion HKD, supported by positive clinical trial results for its drug [6]. - China Life (02628) received a net buy of 3.83 billion HKD, with expectations of steady growth in profits and new business value (NBV) [7]. Group 3: Sector Trends and Market Sentiment - The technology sector showed mixed results, with Meituan (03690) and Alibaba (09988) receiving net buys of 3.33 billion HKD and 3.29 billion HKD, respectively, while Tencent faced a net sell of 5.83 billion HKD [7]. - The AI sector is expected to be a key driver for Hong Kong tech stocks, with improved market sentiment due to easing trade tensions between China and the U.S. [7]. - Horizon Robotics (09660) reported a revenue increase of 67.6% year-on-year, indicating strong growth in the autonomous driving market [8]. Group 4: ETF and Fund Flows - Northbound capital also sold off ETFs, with the Tracker Fund of Hong Kong (02800) and Hang Seng China Enterprises Index (02828) facing net sells of 118.86 billion HKD and 47.76 billion HKD, respectively [9]. - Despite the selling pressure, there is an expectation for continued foreign capital inflow into the Chinese market, although the importance of foreign capital in the Hong Kong market has decreased [9].

Core Viewpoint - CICC reports that Kangfang Biopharma (09926) achieved a 37.75% year-on-year revenue growth in the first half of the year, aligning with the bank's expectations [1] Group 1: Financial Performance - The company's performance meets CICC's expectations, leading to a maintenance of earnings forecasts for the next two years [1] - CICC has raised the target price for the company by 87.5% to HKD 225 [1] Group 2: Product Development - The clinical success rate for AK112 has been upgraded by CICC, and the forecast for the Summit AK112 re-licensing has been included in the valuation [1] - Core drugs, AK104 and AK112, have been included in the national medical insurance catalog, indicating strong clinical advantages and high recognition among medical professionals [1] Group 3: Market Outlook - Given the significant clinical advantages and high acceptance of the products, along with accelerated sales investments by the company, CICC holds an optimistic view on domestic sales for these two products [1]

Core Viewpoint - CICC reports that Kangfang Biopharma (09926) achieved a 37.75% year-on-year revenue growth in the first half of the year, aligning with the bank's expectations [1] Group 1: Financial Performance - The company’s performance meets CICC's expectations, leading to a maintenance of earnings forecasts for the next two years [1] - CICC has raised the target price for the company by 87.5% to HKD 225 [1] Group 2: Product Development - The clinical success rate for AK112 has been upgraded by CICC, and the forecast for the re-licensing of Summit AK112 has been included in the valuation [1] - Core drugs, AK104 and AK112, have been included in the national medical insurance directory, indicating strong clinical advantages and high recognition among medical professionals [1] Group 3: Market Outlook - Given the significant clinical advantages and high acceptance of the products, along with the company's accelerated sales investment, CICC holds an optimistic view on the domestic sales of these two products [1]

Core Viewpoint - The report from交银国际 indicates a significant potential for康方生物's HARMONi study to achieve statistically significant overall survival (OS) results due to a larger sample size [1] Financial Forecasts - The overseas peak sales forecast for康方生物 has been raised to $16.5 billion [1] - The financial projections for the group from 2025 to 2027 have been adjusted [1] - The target price for康方生物 has been increased from HKD 140 to HKD 183, maintaining a "Buy" rating [1] Sales Performance - The company's commercial sales revenue for the first half of the year increased by 49% year-on-year to RMB 1.4 billion [1] - The growth in sales is primarily attributed to the inclusion of the core dual antibody products卡度尼利 and依沃西 in the medical insurance catalog at the beginning of the year [1] - The commercialization of PCSK9 and IL12/IL23 has also contributed to the sales growth [1] - The sales team has over 1,200 members and continues to enhance the oncology and specialty drug divisions [1]

Core Viewpoint - The report from CMB International indicates that with a larger sample size in the HARMONi study, there is a significant likelihood that the final analysis of overall survival (OS) will reach statistical significance [1] Group 1: Financial Projections - The overseas peak sales forecast for the product has been raised to $16.5 billion [1] - The financial forecasts for the group from 2025 to 2027 have been adjusted [1] - The target price has been increased from HKD 140 to HKD 183, maintaining a "Buy" rating [1] Group 2: Sales Performance - The company's commercial sales revenue increased by 49% year-on-year to RMB 1.4 billion [1] - The growth is primarily attributed to the inclusion of core dual-antibody products, Cardunili and Ivosidenib, in the medical insurance catalog at the beginning of the year [1] - The sales team has over 1,200 members and continues to enhance the oncology and specialty drug divisions [1]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 205.69 [1][5][11] Core Views - The company reported significant revenue growth in 1H25, with total revenue reaching CNY 1.41 billion, a year-on-year increase of 37.8%, driven primarily by product sales which grew by 49.2% year-on-year [1][4] - The company is benefiting from the clinical and statistical significance of overall survival (OS) in the HARMONi-A study for its product, Ivoris monoclonal antibody, which solidifies its position as a best-in-class (BIC) treatment [2][3] - The company is expanding its clinical trials both domestically and globally, with 10 domestic and 3 global clinical trials for Ivoris monoclonal antibody underway, indicating a strong pipeline and potential for market expansion [2][3] Revenue and Sales Growth - In 1H25, the company's product revenue was CNY 1.40 billion, reflecting a 49.2% year-on-year increase, supported by the inclusion of Ivoris monoclonal antibody in the medical insurance system, which has rapidly increased its market penetration [4] - The company expects continued strong momentum in its core products, particularly with Ivoris monoclonal antibody and Cardunil monoclonal antibody, which have received medical insurance coverage [4] Financial Forecasts and Valuation - The company forecasts net profits of CNY 0.76 billion, CNY 6.62 billion, and CNY 14.16 billion for the years 2025, 2026, and 2027 respectively, based on a DCF valuation method with a target price of HKD 205.69 [5][11] - The projected revenue for 2025 is CNY 3.35 billion, with a year-on-year growth of 57.62% [10][19]

Core Viewpoint - 康方生物 is undergoing a critical transition from a biotech company to a pharmaceutical enterprise, with significant financial activities and operational challenges ahead [3][4]. Group 1: Financial Activities - On August 28, 康方生物 announced that its two founders will reduce their holdings by selling 1.5 million shares at a price of 149.54 HKD per share, potentially raising nearly 450 million HKD [2]. - The company plans to raise 3.5 billion HKD through a new share issuance, marking the highest frequency of refinancing among peers in the past two years [2]. - As of June 30, 2025, 康方生物 reported a cash balance of 1.45 billion RMB, short-term loans of 510 million RMB, and current liabilities of approximately 2 billion RMB [2]. Group 2: Revenue and Growth - In the first half of 2025, 康方生物 achieved a revenue of 1.4 billion RMB, representing a year-on-year growth of 33%, primarily due to the sales increase of its core products [3][4]. - The sales team has expanded to over 1,200 members, with sales expenses increasing by 30% to 670 million RMB [4]. Group 3: Profitability and Losses - 康方生物 has not yet achieved profitability, with losses widening from 250 million RMB in the first half of 2024 to 590 million RMB in the first half of 2025 [4]. - The increase in losses is attributed to a larger investment loss in partner Summit, which grew from 30 million RMB to 190 million RMB, and a rise in R&D expenses by 137 million RMB compared to the previous year [4]. Group 4: Product Pipeline - 康方生物 has seven self-developed products approved for market, with 12 products in Phase III clinical trials and another 12 in Phase I/II clinical research [4]. - The company aims to become a leading global biopharmaceutical enterprise by focusing on innovative drug development and establishing a world-class production system [4].

智通财经APP获悉，小摩发布研报称，康方生物(09926)上半年业绩表现低于预期，主要是利润率下降和 营运支出高于预期，该行相信，最值得留意是集团宣布HARMONi-A在最终分析达到总生存期(overall survival)的统计显著性，这突显ivonescimab的差异化优势及其成为下一代关键免疫疗法之一的潜力。该 行指，在12种药物的第三期或注册临床试验正进行中，未来几年其可持续发展将面临许多潜在驱动因 素。该行将其目标价由99港元上调至166港元，其评级为"增持"。 该信息由智通财经网提供 ...

Core Viewpoint - Morgan Stanley's report indicates that Kangfang Biopharma (09926) underperformed in the first half of the year, primarily due to declining profit margins and higher-than-expected operating expenses. However, the announcement of HARMONi-A achieving statistical significance in overall survival highlights the differentiated advantage of ivonescimab and its potential as a next-generation key immunotherapy [1] Group 1 - The company's half-year performance was below expectations, driven by a decrease in profit margins and increased operating expenses [1] - The report emphasizes the significance of the HARMONi-A trial results, showcasing the potential of ivonescimab as a leading immunotherapy [1] - There are currently 12 drugs undergoing Phase III or registration clinical trials, indicating multiple potential growth drivers for the company in the coming years [1] Group 2 - Morgan Stanley raised the target price for Kangfang Biopharma from HKD 99 to HKD 166, maintaining an "Overweight" rating [1]

8月28日，康方生物（09926.HK）公告，两位创始人将通过配售分别减持150万股。按每股配售价149.54 港元计算，两位创始人可共套现近4.5亿港元。 减持的两位创始人是：康方生物董事会主席、总裁兼首席执行官夏瑜，执行董事、副总裁兼首席科学官 李百勇。 除了创始人配售老股外，康方生物此次还将发行新股，计划通过发行新股募资35亿港元。康方生物近两 年的再融资频次是同行中最高的，2024年，在资本寒冬下，康方生物通过两次配售新股分别募得11.7亿 港元、19.2亿港元。 在不断扩大的研发投入和商业推广投入下，康方生物的资金消耗速度很快，截至2025年6月底，其账面 现金余额为14.5亿元人民币，短期借款5.1亿元，流动负债约20亿元。 康方生物是一家总部位于广东中山的创新药企，2024年5月，因其核心药物在头对头临床试验中击败全 球"药王"K药而声名大噪。在2025年创新药股市热潮中，康方生物的股价从年初的58港元/股上涨至8月 27日的历史最高点179港元/股。 8月28日配售公告发布后，康方生物股价下挫，截至上午收盘，下跌4.2%，报150港元/股，总市值1350 亿港元，市值在创新药企中排在第7位。 ...